MedinotecMDNC 24 PS Ratio is 6.00 as of Jul. 07, 2026, which is 19% below its 10-year median of 7.42. GuruFocus rates MDNC with a GF Score™ of 24/100. The stock has 2 warning signs investors should review.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Medinotec's share price is $5.00.
Medinotec's Revenue per Share for the trailing twelve months (TTM) ended in Feb. 2026 was $0.83. Hence, Medinotec's PS Ratio for today is 6.00.
The historical rank and industry rank for Medinotec's PS Ratio or its related term are showing as below:
MDNC'
s PS Ratio Range Over the Past 10 Years
Min: 5.08 Med: 7.42 Max: 58.14
Current: 6
During the past 5 years, Medinotec's highest PS Ratio was 58.14. The lowest was 5.08. And the median was 7.42.
During the past 12 months, the average Revenue per Share Growth Rate of Medinotec was 6.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 113.60% per year.
During the past 5 years, Medinotec's highest 3-Year average Revenue per Share Growth Rate was 113.60% per year. The lowest was 113.60% per year. And the median was 113.60% per year.
Back to Basics: PS Ratio
Medinotec (OTCPK:MDNC) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Medinotec PS Ratio Related Terms
Medinotec PS Ratio Historical Data
* Premium members only.
The historical data trend for Medinotec's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Medinotec's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medinotec PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medinotec's PS Ratio distribution charts can be found below:
* The bar in red indicates where Medinotec's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Medinotec's Share Price of today is $5.00. Medinotec's Revenue per Share for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.83.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Medinotec (MDNC) has a PS Ratio of 6.00 as of Jul. 07, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Medinotec and its competitors. This is 19% below median its historical median of 7.42. Over the past decade, Medinotec's PS Ratio has ranged from 5.08 to 58.14.
Is Medinotec's PS Ratio too high?
Medinotec's current PS Ratio of 6.00 is 19% below median its 10-year median of 7.42. Over the past 10 years, this metric has ranged from a low of 5.08 to a high of 58.14. The Medical Devices & Instruments industry median PS Ratio is 2.94. Medinotec's value of 6.00 is 104.1% above this industry median. Overall, Medinotec has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Medinotec's PS Ratio compare to NVNO and APYX?
Medinotec's PS Ratio of 6.00 can be compared against companies in the Medical Devices & Instruments industry. The industry median PS Ratio is 2.94. Medinotec's value of 6.00 is 104.1% above this benchmark. Historically, Medinotec's own PS Ratio has ranged from 5.08 to 58.14 over the past decade. While the company's 10-year median is 7.42 vs. the industry median of 2.94, Medinotec has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.94, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medinotec's current PS Ratio of 6.00 is 104.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Medinotec and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medinotec's current PS Ratio is 6.00, which is 19% below median its own 10-year median of 7.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medinotec stock overvalued right now?
Medinotec (MDNC) has a current PS Ratio of 6.00. The current PS Ratio is 6.00, which is 19% below median its 10-year median of 7.42 and 104.1% above the Medical Devices & Instruments industry median of 2.94. Medinotec's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Medinotec (MDNC), the current PS Ratio is 6.00 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medinotec Inc is a medical device manufacturing and distribution company engaged in tracheal non-occlusive airway dilation technology and medical device design. It generates revenue from two sources: internally designed and manufactured medical devices and distribution of third-party medical products under exclusive or non-exclusive agreements in defined territories. Its products include the Trachealator, the Outflo Aortic Valve Dilation Balloon Catheter, and the Cape Cross family of PTCA balloon catheters. It also distributes a range of cardiology and renal dialysis products on behalf of multinational manufacturers, mainly in South Africa. Its segments are Inside the United States and Outside the United States, with Outside the United States generating maximum revenue.
24GF Score
Get the complete analysis for MDNC
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDNC has been successfully added to your 
